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The current approach of morbidity control of schistosomiasis, a helminth disease of poverty with considerable
public health and socioeconomic impact, is based on preventive chemotherapy with praziquantel. There is a
pressing need for new drugs against this disease whose control entirely depends on this single drug that has
been widely used over the past 40 years. We argue that a broader anthelminthic approach supplementing
praziquantel with new antischistosomals targeting different parasite development stages would not only increase
efficacy but also reduce the risk for drug resistance. Repositioning drugs already approved for other diseases provides a
shortcut to clinical trials, as it is expected that such drugs rapidly pass the regulatory authorities. The antischistosomal
properties of antimalarial drugs (e.g., semisynthetic artemisinins, synthetic trioxolanes, trioxaquines and mefloquine)
and of drugs being developed or registered for other purposes (e.g., moxidectin and miltefosin), administered alone or
in combination with praziquantel, have been tested in the laboratory and clinical trials. Another avenue to follow is the
continued search for new antischistosomal properties in plants. Here, we summarise recent progress made in
schistosomiasis chemotherapy, placing particular emphasis on repositioning of existing drugs against schistosomiasis.
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Schistosomiasis describes a complex of acute and mainly
chronic helminth infection with considerable adverse
influence on people’s health and wellbeing [1, 2]. The
disease is one of today’s foremost neglected tropical dis-
eases (NTDs) and a disease of poverty [3, 4]. The global
burden of schistosomiasis is estimated at 2.6 million
disability-adjusted life years (DALYs) [5]. Although the
number of healthy days lost annually is far below those
calculated for HIV/AIDS, malaria and tuberculosis, the
perceived importance of schistosomiasis is now more real-
istic than 10–15 years ago. Indeed, due to the inclusion of* Correspondence: jennifer.keiser@unibas.ch
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uria and exercise intolerance [6, 7], which were not pre-
viously counted by the Global Burden of Disease (GBD)
study, schistosomiasis now comes second on the list of
18 (after the intestinal nematodes that are counted to-
gether) NTDs put forth by the World Health
Organization (WHO) [5, 8].
Schistosomiasis is caused by one of six different spe-
cies of the trematode worm Schistosoma, with the great
majority of cases either infected with Schistosoma
haematobium, S. japonicum or S. mansoni [2, 9]. The
African continent harbours both S. haematobium and
S. mansoni with an estimated 90% of all cases in the world
concentrated in sub-Saharan Africa [2, 10]. S. mansoni
additionally occurs in Latin America, most import-
antly in Brazil [11], while S. japonicum remains en-
demic in seven provinces of the People’s Republic of
China, The Philippines and three small Indonesian foci
[12]. S. guineensis, S. intercalatum and S. mekongi are not
only in a clear minority, but also geographically limited; the
former two along parts of the Congo River and in lowerle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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restricted to small foci around the border between
Cambodia and Lao People’s Democratic Republic [14].
The pathology characterising schistosomiasis is pri-
marily the result of immune responses against schisto-
some eggs trapped in the tissues, but blood loss caused
by the adult worm is also an important symptom.
Haematuria and dysuria are typical early signs of the
urogenital form of the infection (caused by S. haemato-
bium) with kidneys and bladder becoming seriously
affected in chronic infections [15]. The intestinal form
(caused by any of the five other species) results in blood
in the stool and diarrhoea with the liver and spleen af-
fected in the longer term [2, 15]. Morbidity has been
strongly suppressed as a result of preventive chemo-
therapy that is the periodic large-scale administration
of praziquantel to school-aged children and other high-
risk groups without prior diagnosis [16]. A systematic
review and geostatistical analysis pertaining to schisto-
somiasis in sub-Saharan Africa suggests that the preva-
lence and distribution of the disease has declined in
recent years, most likely as a result of preventive
chemotherapy, coupled with social and economic devel-
opment [10]. Of note, in 2015, among the 218.7 million
people requiring preventive chemotherapy against
schistosomiasis, 65.2 million people were administered
praziquantel, owing to a global coverage of 29.8% [17].
Praziquantel, a highly efficacious pyrazinoisoquinoline
derivative with a good safety profile and a broad spectrum
against helminth infections, remains the drug of choice
for schistosomiasis chemotherapy since almost 40 years
[18, 19]. Thanks to the good therapeutic and safety index
[20], and a donation programme from Merck, praziquan-
tel is the cornerstone in the WHO promoted global strat-
egy against schistosomiasis. Despite reports of strains that
have become tolerant or even resistant to praziquantel
[21–23], these findings are of little clinical relevance thus
far. In the late 1970s/early 1980s, praziquantel replaced
the first useful antischistosomal drugs oxamniquine,
another quinoline derivative effective against S. mansoni
[24, 25], and metrifonate, an insecticide based on inhib-
ition of acetyl-cholinesterase that is efficacious against S.
haematobium [24, 26]. Before that, in the early part of the
1900s (up to around 1975), a number of less efficacious
compounds were used in spite of major adverse events,
e.g., hycanthone, luchantone, amoscanate, niridazole and
oltipraz. Antimony potassium tartrate, a potentially poi-
sonous metalloid without distinctive effect, but known as
an emetic and medicine against various ailments since an-
cient times marked the end of non-specific schistosomia-
sis chemotherapy [27, 28].
Schistosomiasis control is at a pivotal point in major
endemic areas. Elimination has been articulated as an
aspiration, but it is clear that it cannot be based onpraziquantel alone [29]. The emphasis on preventive
chemotherapy campaigns using praziquantel has led to
the misconception that there is little need for alternative
compounds. Drug discovery run by academic research
groups rather than industry has resulted in a variety of
new leads, which might serve as starting points for anti-
schistosomal drug discovery. We review progress in re-
search and development of antischistosomal drugs and
update the intriguing field how new and old drugs can
be utilized in concert against schistosomes in different
developmental stages. Our focus is on repositioning of
drugs used against diseases other than schistosomiasis,
as this strategy might advance existing drugs more rap-
idly into clinical use for a typical disease of poverty with
a deficient market.
Research and development of antischistosomal
drugs
Setting the scene
The WHO road map for the global control of the NTDs
includes schistosomiasis [30]. However, control – let
alone elimination – of schistosomiasis has proven diffi-
cult because of rapid re-infection due to limited means
of control for the intermediate host snail and absence of
sanitary facilities in most endemic areas [29, 31, 32]. A
variety of approaches, including water, sanitation and hy-
giene (WASH), information, education and communica-
tion (IEC), behavioural change and snail control, have
been employed, but preventive chemotherapy with prazi-
quantel has been the fundamental approach since the
early 1980s. If, for any reason, this line of attack would
falter, there is currently no other remedy to put in its
place and the next generation of anthelminthic drugs is
yet to appear. Since the last surge of drug discovery for
parasitic worm diseases in the 1970s, resulting in the
marketing of praziquantel and ivermectin that, together,
cure several of the major helminth infections [33], no
new drugs for helminthiases have been approved. It is
even more worrisome that the drug discovery and devel-
opment pipeline for NTDs has run dry over the past
40 years [34].
Pre-emptive action is urgently needed to assure that
chemotherapy does not dwindle, particularly not in
low- and middle-income countries where schistosomia-
sis inflicts a disproportionately high burden of disease.
Judging from the veterinary field, development of drug
resistance in helminthiasis can be swift [35] and the
situation with respect to malaria is a constant reminder
of this risk [36].
Laboratory studies
The search for new drugs against schistosomiasis has
taken various directions, including testing natural com-
pounds, target-based drug discovery or compounds
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an important role in antischistosomal drug discovery
[37] and many products of potential value have been
found this way.
Natural plant products are an important source of
antiparasitic drugs [38, 39]. This is not only poten-
tially fruitful with respect to isolation of new active
principles, but would also facilitate the elucidation of
their mechanism of action. Herbal extracts have
drawn attention due to their broad range of biological
activity and the large variety of chemical structures
presented. This untapped source of potential anthel-
minthic compounds remains a novelty and many pa-
pers on this topic exist. For example, a search on
PubMed on January 23, 2017 using the search terms
‘plant extract’ and ‘schistosomiasis’ yielded 227 publi-
cations, while ‘plant extract’ and ‘Schistosoma’ yielded
194. It should, however, be noted that not only hits
active against schistosomes but also against the snail
intermediate host (plant molluscicides) and sometimes
against other parasites were discovered [40].
Another strategy is based on using available biologic-
ally active natural compounds and their directed chem-
ical modification as recently demonstrated for new
triphenylphosphonium derivatives of betulin and betuli-
nic acid [41]. However, rather than discussing the many
different schistosomicidal agents discovered in plant ex-
tracts here, we refer to recent reviews of the field by de
Moraes [42] and Neves and colleagues [43].
The recent sequencing of the genomes of the three key
schistosome species has resulted in the discovery of many
new possible vaccine and drug targets [44–46]. Moreover,
it is conceivable that drug discovery programmes using
molecular modelling strategies will increasingly contribute
to antischistosomal drug discovery [47, 48].
Work on the antischistosomal properties of various
antimalarial drugs, notably semi-synthetic artemisinins,
synthetic trioxolanes and mefloquine [49], as well as a
few more discussed below, have shown that repurposing
of drugs may be the more rapid approach as it provides
a shortcut to clinical trials and rapid passage through
regulatory authorities. Indeed, the idea of repositioning
drugs is an inexpensive, yet effective source of new lead
compounds for use against schistosomiasis, which has
already resulted in several promising leads [50].
While the antimalarials are the most well-known
group of drugs shown to have a strong action against
schistosomes in addition to what they are intended for
[49] several other pharmaceutical groups also contain
compounds with such effect, notably drugs used for can-
cer therapy [51]. Table 1 contains a list of candidate
drugs described in some detail with regard to use against
schistosomiasis summarising their effect on adult and ju-
venile schistosomes, including dosage.Antimalarials
Natural products have played a major role in drug dis-
covery, in particular for malaria treatment and prophy-
laxis. While quinine and artemisinin come straight from
natural plants, several semi-synthetic agents (e.g., arte-
mether and artesunate) [52, 53] and synthetic derivatives
have been at the centre of attention for more than
15 years. Hybrid molecules comprising of a 1,2,4-triox-
ane domain (as in the artemisinins) linked to amino
quinoline (as in chloroquine) were developed in the late
1990s; these trioxaquines thus have a dual mechanism of
action, which improves the antimalarial activity over
each single compound [54]. Meanwhile, some trioxa-
quines have also been analysed for their antischistosomal
properties with promising results [55], suggesting that
the heme molecule is an important target for these com-
pounds [56]. The mechanisms of action of the 1,2,4-
trioxolanes remains unknown but is clearly connected
with the peroxide bond, which they share with the
artemisinins. The compounds OZ78, OZ209 and
OZ288 were first studied in S. mansoni- and S. japoni-
cum-rodent models [57] and several representative
compounds with high antischistosomal activity were
identified, some of which – such as OZ418 – have im-
proved pharmacokinetic properties [57–60]. The high-
est activity (worm burden reduction of 72%) was seen
after treating hamsters infected with adult S. mansoni
with OZ288 [57] and mice with OZ418 (worm burden
reduction of 86%) [59]. Recently, using rodents in-
fected with S. mansoni, Mossallam and colleagues
showed high activity of OZ277 combined with pipera-
quine phosphate, a bisquinoline first synthesised in the
1960s and used extensively in the People’s Republic of
China until resistant strains of Plasmodium falcip-
arum arose [61]. Bridged 1,2,4,5-tetraoxanes, tricyclic
monoperoxides, bridged 1,2,4-trioxolanes, silyl perox-
ides and hydroxylamines were also studied with the
highest antischistosomal activity (in particular in vitro)
observed for trioxolanes and tricyclic monoperoxides [62].
Van Nassauw et al. [63] were the first to report an anti-
schistosomal effect by mefloquine, an effective antimalar-
ial agent that was introduced as a successor to
chloroquine [64]. They noted that mefloquine significantly
reduces egg production in S. mansoni-infected mice but
they saw no effect on worm burden. Later papers also re-
ported impact on egg maturation but in contrast to this
first paper, researchers all noted strong effect with respect
to worm burden [65–67]. When different amino ethanols,
such as halofantrine, lumefantrin, quinine and mefloquine,
were tested in S. mansoni-infected mice, mefloquine
showed the highest activity [65]. A further important find-
ing is that, in contrast to the effect by artemisinins and
praziquantel that target juvenile and adult schistosomes,
respectively, all parasite stages are equally affected by
Table 1 Activity observed with drug discovery candidates in the S. mansoni-mouse model





Artemether 300 mg/kg/day for 2 days 85.4–98.3% 70% [52]
Artesunate 150 or 300 mg/kg/day for 7 days 34–49% 67–77% [53]
Bisquinoline cyclen derivative 400 mg/kg single dose 12.3% Not done [74]
Bisquinoline cyclen derivative
(Fe++ complex)
400 mg/kg single dose 88.4% Not done [74]
Bisquinoline cyclen derivative
(Mn++ complex)
400 mg/kg single dose 74.5% Not done [74]
Chlorambucil 2.5 mg/kg/day for 5 days 22.7% 75.8% [77]
Clofazimine 400 mg/kg single dose 82.7% Not done [84]
2,3-dianilinoquinoxaline MMV007224 400 mg/kg single dose 40.8% Not done [71]
N,N’-Diarylurea MMV665852 400 mg/kg single dose 52.5% Not done [71]
N,N’-Diarylurea MMV665852 analogs 400 mg/kg single dose 9.3–36% Not done [72]
Doramectin 10 mg/kg single dose 60.1% Not done [84]
Mefloquine 400 mg/kg single dose (adult),
100 mg/kg (juvenile)
77.3% 94.2% [65]
Mefloquine derivatives 100 mg/kg single dose 0-87% Not done [69]
Miltefosin 20 mg/kg daily for 5 days 95.4% 75.5% [75]
OZ78 200 mg/kg single dose (juvenile),
400 mg/kg single dose (adult)
0% 82% [57]
OZ209 200 mg/kg single dose (juvenile),
400 mg/kg single dose (adult)
16% 85% [57]
OZ288 200 mg/kg single dose (juvenile),
400 mg/kg single dose (adult)
52.2% 95.4% [57]
OZ418 200 mg/kg single dose (juvenile),
400 mg/kg single dose (adult)
80% 100% [59]
Perhexiline maleate 23, 70 and 400 mg/kg single dose Not given Not given [83]
Piperaquine/OZ277 (Synriam) 40 mg/kg arterolane (OZ277) and
200 mg/kg piperaquine
88.7% 85.4% [61]
Ferroquine 200 mg/kg and 800 mg/kg single dose 19.4% and 35.6% Not done [73]
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served testing the activities of the erythro and threo iso-
mers and racemates of mefloquine [66]. In addition,
mefloquine had a strong effect on tissue egg load and
number of liver granulomas [67]. Additionally, activity has
been shown against S. japonicum [68] and S. haemato-
bium [69]. Moreover, synergistic effects were observed
when mefloquine and praziquantel were combined in the
animal model [70]. Finally, when evaluating the antischis-
tosomal activities of nine mefloquine-related compounds
belonging to the 4-pyridinemethanols, 9-phenanthren-
methanols, and 4-quinolinemethanols, high activity was
observed for WR7930 and enpiroline, an antimalarial
drug, which had already undergone clinical testing [69].
Another approach is represented by the screening of a
library for antischistosomal properties in 200 diverse
drug-like and 200 probe-like compounds with confirmed
in vitro activity against P. falciparum obtained from theMedicines for Malaria Venture (MMV). Thirty-four
compounds were found active in in vitro screens, two of
which (N,N’-diarylurea and 2,3-dianilinoquinoxaline)
identified as early leads after extensive in vitro and
in vivo testing; they also had good pharmacokinetic pro-
files and low cytotoxic potential. In more detail, in vivo
experimental work with S. mansoni revealed worm bur-
dens reductions of 53% and 41%, respectively, compared
to controls [71]. Follow-up studies evaluated the
structure-activity relationships of 46 commercially avail-
able analogues of MMV665852 larval and adult S. man-
soni worms in vitro with subsequent in vivo studies.
Despite satisfactory in vitro results and in silico predic-
tions, only one compound resulted in a statistically sig-
nificant worm burden reduction (66%) in S. mansoni-
infected mice. The authors concluded that there is a
need to synthesise compounds with improved solubility
and pharmacokinetic properties [72].
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an antimalarial in late-stage drug development. However,
the drug revealed only moderate in vitro activity against
both larval and adult stages of S. mansoni and low
in vivo activity [73].
Further, a series of synthetic tetra-azamacrocyclic de-
rivatives and their metal complexes, which are effective
antimalarial agents were synthesised, characterised and
screened in vitro against different schistosomal stages
(schistosomula and adult worms). Three compounds
(the bisquinoline derivative of cyclen and its Fe2+ and
Mn2+ complexes), highly active in vitro, were selected
for in vivo experiments using the S. mansoni-mouse
model. The worm burden reductions were 12%, 88% and
75%, respectively. The additional fact that the Fe2+com-
plex exhibited an activity comparable to that of prazi-
quantel must be deemed a strong indication of a novel
drug lead for schistosomiasis [74].Anticancer drugs
It has further been demonstrated that miltefosine, an
anticancer alkylphosphocholine, possesses significant
activity against different developmental stages of S. man-
soni [75]. This lead has been further developed using a
nanotechnological adjuvant approach based on lipid
nanocapsules [76]. The results of this study indicated a
strong schistosomicidal effects against both the invasive
and the immature stage, further indicated by a signifi-
cant reduction in worm burdens [76].
Chlorambucil, a nitrogen mustard alkylating agent that
has so far mainly been used in the treatment of chronic
lymphocytic leukemia, low-grade non-Hodgkin’s lymph-
oma and Hodgkin’s disease, and is on the WHO list of
essential medicines, recently demonstrated an antischis-
tosomal in vitro effect in the form of progressive reduc-
tions of worm viability in a dose-dependent manner
[77]. In vivo, chlorambucil induced a significant reduc-
tion in the total worm (S. mansoni) burden, including 89%
and 87% intestinal and hepatic egg count reduction,
respectively, with the highest in vivo efficacy against the
juvenile stage of S. mansoni [77].
Cowan et al. studied the approved oncology drug set
of the National Cancer Institute’s Developmental Thera-
peutic Program against S. mansoni in vitro and in vivo.
Of six compounds studied in vivo, the highest activity
was observed with two kinase inhibitors – trametinib
and vandetanib with respective worm burden reductions
of 63.6% and 48.1% – after a single oral dose of 400 mg/
kg [78]. In schistosomes, conserved protein kinases pos-
sess pivotal roles contributing not only to reproduction
processes, but also to the pathology of schistosomiasis
[79]. Kinases represent therefore attractive targets for
new-generation antischistosomal drugs.Miscellaneous products
The aryl hydantoin Ro 13–3978 is a compound discov-
ered by Hoffmann-La Roche more than two decades ago
with good in vivo antischistosomal activity [80]. Ro 13–
3978 is structurally similar to the antiandrogenic drug
nilutamide, which has moderate antischistosomal prop-
erties [81]. To reduce the antiandrogenic effect, Wang
and colleagues designed a number of analogs incorporat-
ing substructures and functional groups and identified
several compounds with high antischistosomal efficacy
that were less antiandrogenic [82].
Other unrelated drugs have also received interest. For
example, a recent report has shown that perhexiline
maleate, a drug used for heartburn (angina) by improv-
ing myocardial oxygen utilization, surprisingly reacted
when a library with an ATP-based luminescent assay
based on S. mansoni schistosomula was screened [83].
This drug was found to exhibit a marked lethal effect on
all S. mansoni parasite life stages in vivo resulting in
tegumental damage in the adult male worm and im-
paired egg production in the female worm [83]. Al-
though the preliminary in vivo experiments only
resulted in moderate egg reductions, this drug warrants
deeper investigation and if found as useful clinically as
the in vivo experiments indicate (Table 1), the road to
registration should be short.
In another scheme, researchers found 121 compounds
active against S. mansoni schistosomula out of 1 600
compounds approved by United States’ Food and Drug
Administration (FDA). When advancing to an adult
worm screen, the list shrank by more than 70% and
when available pharmacokinetic and toxicity data for
these compounds were considered, only 11 remained,
two of which (i.e., doramectin and clofazimine) resulted
in worm burden reductions of 60% and 83%, respectively,
when tested in vivo against S. mansoni [84]. These two
active drugs are widely available and constitute excellent
starting points for developing novel drug classes against
schistosomiasis.
Similarly, Abdulla et al. [85] tested a large number of
natural and synthetic compounds against S. mansoni
schistosomula, many of which were approved drugs to
find starting points for developing new leads. The vari-
ous compounds identified have been posted online as a
community resource.
Clinical studies
Drug discovery and follow-up development is an expen-
sive endeavour. Repositioning of drugs already approved
for human use offers a way out of this impasse, at least
from the part of the studies concerned with safety. Phase
II/IV clinical trials are still needed to make sure that the
drugs work as planned with respect to the pathogens
they are supposed to protect against. In an endeavour to
Table 2 Summary of four recent clinical trials with drugs repositioned for use against chronic infections with S. mansoni and
S. haematobium









Artesunate Not done Not done 25 85 [104]
Mefloquine Not done Not done 21 74 [104]
Mefloquine-artesunate Not done Not done 61 96 [104]
Mefloquine-artesunate-praziquantel Not done Not done 29 96 [105]
Moxidectin 13 71 15 9 [103]
Synriam 7 65 11 0 [103]
Praziquantel-Synriam 27 78 60 96 [103]
ARA Arachidonic acid 13–50 0–64 Not done Not done [109]
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most widely studied drugs, as summarised in Table 2.
The artemisinins have been discussed extensively in pre-
vious reviews [49, 50, 58, 86–91]. Briefly, leaf extracts
from the plant Artemisia annua recommended in Chinese
traditional medicine against malaria (and other ailments),
constituted the starting point for the development of the
artemisinin-based combination therapy (ACT) currently
in use against this infection [92, 93]. The expansion of the
therapeutic effect of the artemisinins from Artemisia
leaves to include S. japonicum schistosomes discovered in
the early 1980s was completely unexpected [94]. This
effect by the semi-synthetic artemisinin derivative arte-
mether was later also confirmed for S. mansoni [52]
and S. haematobium [95] in experimental animals. Sub-
sequent clinical trials confirmed the protective efficacy
for artemether [96, 97] and artesunate [98] and encour-
aged many articles discussing the advantage (and
potential disadvantages) of including the artemisinins
along with praziquantel in areas endemic for schisto-
somiasis and co-endemic for malaria [88, 90].
In more detail, the antischistosomal effect of the artemi-
sinins is primarily directed against juvenile schistosomes,
while that of praziquantel works on the very day of infec-
tion, after which the parasite does not become susceptible
against this drug again until it reaches adulthood 4–5
weeks later [87]. Although the periods of susceptibility
vary slightly between the different schistosome species in-
fective to man, the principle of age-correlated impact re-
mains the same. Surprisingly, but advantageously, the
drugs thus complement each other [87]. Currently, pre-
ventive chemotherapy is based on the administration of
praziquantel only, which means that only adult worms are
killed and that the person treated will be fully repopulated
from surviving schistosomula about a month later. Com-
bination therapy would improve the situation but it must
also be iterated for as long as the patient lives in an en-
demic area if precautions against reinfection are not taken(which is difficult and costly in practice). The risk for drug
resistance due to widespread use of monotherapy with
artemether or artesunate, however, must be taken ser-
iously as the emergence of malaria parasites resistant to
the artemisinins have shown [99, 100]. However, used in
non-malarious areas, this risk should be limited.
There is no single prophylactic drug that can reliably
protect against schistosome infection, but the combin-
ation of praziquantel and artemether comes close [101].
On the other hand, the use of this kind of prophylaxis
can only be recommended in very special cases; for ex-
ample during flood relief work in the People’s Republic
of China and perhaps when the final steps of elimination
of the infection are taken.
Arterolane maleate (OZ277) is one of the first fully syn-
thetic non-artemisinin antimalarial compounds marketed,
hence offering a treatment alternative to the artemisinins
(Table 2). The arterolane maleate/piperaquine combin-
ation, licensed in 2011 as an antimalarial drug under the
name of Synriam® [102], has been investigated for activity
against chronic schistosome infections in humans. Two
single-blind, randomised exploratory Phase II trials have
been carried out in adolescents infected with S. mansoni
and S. haematobium in Côte d’Ivoire with cure rate (CR)
and egg reduction rate (ERR) based on geometric mean
and safety as endpoints. Synriam® showed low efficacy
against S. haematobium with CR and ERR of 11% and 0%,
respectively. Against S. mansoni a CR of 7% and an ERR
of 64.9% was observed [103]. Despite the low efficacies ob-
served it might be worthwhile to assess the efficacy of
Synriam against juvenile schistosome infections.
A few years ago the efficacy and safety of mefloquine
(25 mg/kg) was studied in a randomised, exploratory
open-label trial against S. haematobium. The other treat-
ment arms consisted of artesunate (3 doses of 4 mg/kg),
mefloquine-artesunate (3 doses of 100 mg artesunate
plus 250 mg mefloquine) and praziquantel (40 mg/kg)
alone. CRs of mefloquine, artesunate, mefloquine-
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at day 26 after treatment were 21%, 25%, 61% and 88%,
respectively. Both mefloquine-artesunate and praziquan-
tel alone revealed ERRs in excess of 95% [104]. Based on
the aforementioned report documenting synergistic ef-
fects when mefloquine and praziquantel were combined
[70], a thorough study investigating combination ther-
apy for S. haematobium infection in human subjects
was initiated. When praziquantel-mefloquine and
praziquantel-mefloquine-artesunate combinations were
used, the investigators could not find any increased
efficacy compared to praziquantel alone (CRs from
26% to 33%), but they observed a higher level of side
effects with the mefloquine combinations [105].
Moxidectin, a semisynthetic derivative of nemadectin
produced by fermentation by Streptomyces cyanogriseus
originally developed for the prevention and control of
Dirofilaria immitis (heartworm) and intestinal worms in
dogs [106], is being assessed as an alternative to ivermec-
tin in the treatment of onchocerciasis in humans. In the
frame of this programme its effect on concomitant hel-
minths revealed CR and ERR of 64% and 66%, respectively
in S. mansoni-infected patients [107]. The aforementioned
study by Barda and colleagues recently demonstrated low
efficacy of moxidectin against S. haematobium and low
CR and moderate ERR against S. mansoni [103].
Arachidonic acid (ARA), which is a normal constituent
of cell plasma membranes was studied in schoolchildren
with light, moderate or heavy S. mansoni infection given
a good performance in a proof-of-concept study in chil-
dren with light infections [108]. ARA (10 mg/kg per day
for 15 days) revealed moderate CRs (50% and 60%, re-
spectively) against light infection and low CRs (21% and
20%, respectively) against heavy infection. Praziquantel
and ARA combined elicited 83% and 78% CRs in children
with light and heavy infection, respectively [109].
Discussion
Praziquantel is currently the only fully effective antischisto-
somal drug in use [25]. It has been used in preventive
chemotherapy programmes in many endemic countries, in
some continuously since more than 15 years [25, 110, 111].
However, it is not until recently that preschool-aged chil-
dren and pregnant women were included into the recom-
mended target population for preventive chemotherapy
[112, 113]. Both these groups are now recommended to be
treated with praziquantel when needed; still there are exist-
ing gaps due to drug shortage and lack of a pediatric prazi-
quantel formulation [112]. This expanded access to
praziquantel, including biannual treatment schedules [114]
and use of the drug for the treatment of domestic animals
in the context of zoonotic schistosomiasis [115], increases
the risk for development of resistance and demands aug-
mented monitoring of drug failure and resistance.Drug discovery is indeed essential, since the loss of
praziquantel due to resistance would not only jeopardize
the success achieved, but also close the window of op-
portunity for assembling an integrated approach, e.g.,
combining effective chemotherapy with a different ap-
proach with a longer reach, e.g., a vaccine [116]. This as-
piration rests, however, on fragile grounds as inadequate
funding has held back vaccine development and even if
some good advances have been made [117], we are still
years from potential field application of a schistosomiasis
vaccine. In addition, new drugs are an unconditional ne-
cessity not only to safeguard the efficacy of chemotherapy,
but also because an effect against both juvenile and adult
schistosomes, would also affect transmission allowing lon-
ger intervals between preventive chemotherapy rounds.
Identification of the antischistosomal activity of the
artemisinins constituted the impetus for investigating
the properties of natural products with the aim of devel-
oping new treatments for various parasitic diseases. Al-
though this progress represents a landmark in the
advance towards completely new drugs against schisto-
somiasis (and also malaria), ongoing research on reposi-
tioning existing drugs has already resulted in a wide
range of promising, antischistosomal drug candidates.
Although no drug candidate with as good efficacy as that
of praziquantel has appeared, many drugs show profiles
and efficacies offering the prospect of together covering
the whole spectrum from 1-day-old schistosomula up to
adult worms such as the praziquantel-artemisinin com-
binations. Even drugs that have the same effect on schis-
tosome worms can complement each other as long as
their mechanisms of action differ.
Apart from the advances made with repositioning
drugs, further development of trioxolanes and trioxa-
quines, as well investigation of plant extracts and screen-
ing of libraries, deserve further scientific inquiry.
Continuing in these footsteps, we recommend establish-
ing an international research programme for prospecting
synthetic, semi-synthetic and bioactive compounds from
natural products, including plant molluscicides. In vitro
and in vivo evaluation of chemical constituents belong-
ing to different classes of chemical compounds should
obviously be part of this effort, as should structural de-
termination using genomic and proteomic approaches.
Conclusions
Summarising the progress in the field of antischisto-
somal drug discovery, the sad reality is that in
15 years’ time we will likely have no alternatives to
praziquantel available. There is a pressing need to
strengthen antischistosomal drug discovery, which in-
cludes improving the translational science in aca-
demia, intensify collaborative approaches, including
engagement with the pharmaceutical industry and
Bergquist et al. Infectious Diseases of Poverty  (2017) 6:74 Page 8 of 10persuade donors and policy makers that alternatives
to praziquantel are necessary for sustaining the con-
trol of schistosomiasis and approaching the goal of
eliminating this scourge from mankind.
Research into how drugs act at the fundamental level
is an important research area as this has a high probabil-
ity of discovering superior formulations and combina-
tions. Pursuing this approach, the following axes of
research should be particularly rewarding:
1. profiling existing drugs and drug candidates with
the aim of finding leads to superior derivatives;
2. investigation of different and more efficient
combinations of existing drugs;
3. exploration of disparity between host and parasite
metabolic pathways;
4. analysis of genomes and transcriptomes with the
aim of identifying new drug targets; and
5. monitoring antischistosomal effects in areas where
ACTs are used as first-line drugs against malaria.
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